The Bronchiolitis in Hospitalized Infants Study
Key facts
- Who runs it
- IDeA States Pediatric Clinical Trials Network
- Where
- Little Rock and Omaha, United StatesSee the 2 sites
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- 9 Oct 2023
- Ended
- 14 Apr 2025
- Type of study
- Interventional
- Treatments tested
- Dexamethasone Oral
- Record updated
- 14 September 2023
- Why it stopped
- The study was withdrawn with no participants enrolled due to the need for an IND from the FDA, which significantly expanded the scope of the study beyond what was originally anticipated for a pilot project within this network.
Who can take part
- Age
- 0 months to 24 months
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Infants <24 months of age at time of enrollment
- Admitted to the hospitalist service with a diagnosis of bronchiolitis
- RSV and COVID-19 Negative
- At least one of the following clinical criteria:; personal history of breathing problems; personal history of eczema; parental history of asthma
- Parental ability to speak and read English or Spanish
Who cannot take part
- Currently taking corticosteroids (inhaled or oral) or have taken corticosteroids within 7 days prior to hospitalization (per parental report and chart review)
- Known underlying heart failure, hypertension, gastrointestinal bleeding, liver disease, thyroid disease (per parental report and chart review)
- Preterm Infant (born at < 34 weeks' gestation)
- Diagnosis of asthma
- Admission to the intensive care unit (ICU) at time of enrollment
- Participants (caregivers) who, in the view of the investigator, whom are unlikely able to comply with the protocol requirements
Where in United States
- Arkansas Children's HospitalLittle Rock, United States
- University of Nebraska Medical CenterOmaha, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine whether it is possible to identify, enroll, and deliver the study intervention (the corticosteroid dexamethasone) in hospitalized infants with bronchiolitis.
Read full original descriptionShow less
Participants in this study will be given two doses of dexamethasone within 72 hours of enrollment, followed by 30 days of safety monitoring.
Results of this feasibility pilot study may be used to inform the design of a future randomized controlled trial, whose results in turn could induce a paradigm shift in acute management of bronchiolitis.
The group in the trial
- Dexamethasone AdministrationTreatment being tested
Dexamethasone will be given orally to all consented participants. Two doses will be administered within 12-48 hours, with at least the 1st dose administered during the bronchiolitis hospitalization. If the participant is discharged before the 2nd dose, it will be administered at home.
Treatment: Dexamethasone Oral
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Bronchiolitis in Hospitalized Infants (BroncHI) Study: A Feasibility Trial Aimed to Identify and Treat Hospitalized Infants With Bronchiolitis Most at Risk for Recurrent Wheezing and Asthma
- Record updated
- 14 September 2023